NYSE · Financial Statements

Teladoc Health, Inc. (TDOC) Revenue, Earnings & Financial Statements

$8.49 NYSE: TDOC Market Cap $1.55B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Teladoc Health, Inc. most recently reported annual revenue of $2.5B, a net loss of $200.0M. Revenue grew at an average annual rate of 18.3% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Teladoc Health, Inc.: Revenue rose from $123.0M in 2016 to $2.5B in 2025, a change of +1956.9% over 9 years; net profit was positive in 0 of 10 reported years; operating margin moved from -50.9% to -10.4%, a shift of +40.5 percentage points; the most recent year shows a net loss of $200.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$123.0M$233.0M$418.0M$553.0M$1.1B$2.0B$2.4B$2.6B$2.6B$2.5B
Operating Expenses$186.0M$309.0M$489.0M$634.0M$1.6B$2.3B$16.1B$2.9B$3.6B$2.8B
Operating Profit−$63.0M−$75.0M−$71.0M−$80.0M−$506.0M−$266.0M−$13.7B−$249.0M−$1.0B−$263.0M
Operating Margin-50.9%-32.3%-16.9%-14.5%-46.3%-13.1%-567.3%-9.6%-39.7%-10.4%
Other Income−$11.0M−$32.0M−$26.0M−$29.0M−$70.0M−$119.0M−$10.0M$29.0M$27.0M$27.0M
Interest$3.0M$17.0M$26.0M$29.0M$60.0M$81.0M$22.0M$22.0M$24.0M$20.0M
Depreciation$8.0M$19.0M$36.0M$45.0M$78.0M$220.0M$268.0M$349.0M$383.0M$363.0M
Profit Before Tax−$74.0M−$107.0M−$97.0M−$109.0M−$576.0M−$385.0M−$13.7B−$220.0M−$994.0M−$236.0M
Tax rate (%)-0.7%0.2%-0.1%9.7%15.8%-11.5%0.0%-0.3%-0.8%14.9%
Net Profit−$74.0M−$107.0M−$97.0M−$99.0M−$485.0M−$429.0M−$13.7B−$220.0M−$1.0B−$200.0M
EPS−$1.75−$1.93−$1.47−$1.38−$5.36−$2.73−$84.60−$1.34−$5.87−$1.14

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$661.0M$646.0M$642.0M$641.0M$640.0M$629.0M$632.0M$626.0M$642.0M$614.0M$607.0M$605.0M
Operating Expenses$696.0M$733.0M$1.5B$685.0M$689.0M$750.0M$686.0M$678.0M$678.0M$663.0M$644.0M$633.0M
Operating Profit−$35.0M−$87.0M−$841.0M−$44.0M−$48.0M−$121.0M−$54.0M−$52.0M−$36.0M−$49.0M−$37.0M−$28.0M
Operating Margin-5.3%-13.5%-130.9%-6.9%-7.5%-19.2%-8.6%-8.3%-5.6%-7.9%-6.1%-4.6%
Interest$6.0M$6.0M$6.0M$6.0M$7.0M$6.0M$4.0M$5.0M$5.0M$5.0M$5.0M$5.0M
Profit Before Tax−$25.0M−$79.0M−$834.0M−$32.0M−$48.0M−$111.0M−$40.0M−$50.0M−$34.0M−$61.0M−$38.0M−$26.0M
Tax rate (%)-13.8%-3.4%-0.5%-2.4%-0.5%16.4%19.2%1.4%25.2%-4.9%-2.6%-2.5%
Net Profit−$29.0M−$82.0M−$838.0M−$33.0M−$48.0M−$93.0M−$33.0M−$50.0M−$25.0M−$64.0M−$39.0M−$27.0M
EPS−$0.17−$0.49−$4.92−$0.19−$0.28−$0.53−$0.19−$0.28−$0.14−$0.36−$0.21−$0.15

Over the 10 years reported for Teladoc Health, Inc., borrowings increased from $44.0M in 2016 to $1.0B in 2025, cash stood at $781.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.68 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$304.0M$824.0M$1.5B$1.6B$17.8B$17.7B$4.7B$4.4B$3.5B$3.1B
Current Assets$83.0M$156.0M$533.0M$588.0M$1.1B$1.2B$1.3B$1.5B$1.7B$1.1B
Cash$50.0M$43.0M$424.0M$514.0M$733.0M$893.0M$918.0M$1.1B$1.3B$781.0M
Inventory$0$0$0$0$56.0M$73.0M$56.0M$30.0M$38.0M$38.0M
Receivables$14.0M$27.0M$44.0M$57.0M$169.0M$190.0M$236.0M$230.0M$224.0M$202.0M
Fixed Assets$7.0M$9.0M$10.0M$37.0M$75.0M$74.0M$71.0M$72.0M$57.0M$53.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$16.0M$129.0M$149.0M$3.0M$53.0M$3.0M$0$0$0$0
Other Assets$188.0M$499.0M$737.0M$746.0M$14.6B$14.5B$1.1B$1.1B$283.0M$283.0M
Total Liabilities$73.0M$265.0M$516.0M$589.0M$1.9B$1.7B$2.4B$2.1B$2.0B$1.7B
Current Liabilities$21.0M$40.0M$62.0M$90.0M$333.0M$331.0M$400.0M$421.0M$942.0M$405.0M
Borrowings$44.0M$207.0M$415.0M$470.0M$1.5B$1.3B$1.6B$1.6B$1.6B$1.0B
Other Liabilities$28.0M$58.0M$101.0M$118.0M$395.0M$409.0M$806.0M$474.0M$441.0M$675.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$231.0M$559.0M$1.0B$1.0B$15.9B$16.0B$2.3B$2.3B$1.5B$1.4B

For Teladoc Health, Inc., operating cash flow was positive in 6 of 10 reported years; free cash flow in the latest year was $285.0M; free cash flow was positive in 6 of 10 years; financing activities used $4.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow−$52.0M−$34.0M−$5.0M$30.0M−$54.0M$194.0M$189.0M$350.0M$294.0M$294.0M
Investing Cash Flow$88.0M−$520.0M−$266.0M$14.0M−$617.0M−$82.0M−$184.0M−$313.0M−$135.0M−$275.0M
Financing Cash Flow$3.0M$13.0M$36.0M$35.0M$97.0M−$1.0M−$3.0M$0$0−$4.0M
Net Cash Flow−$5.0M−$7.0M$381.0M$90.0M$219.0M$160.0M$25.0M$205.0M$175.0M−$517.0M
Free Cash Flow−$55.0M−$40.0M−$13.0M$19.0M−$80.0M$185.0M$173.0M$194.0M$283.0M$285.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.25
EV / EBITDA7.61
FCF Yield14.36%
Quick Ratio0.84
Interest Coverage-7.36
Return 1Y25.78%
Return 3Y-50.55%
Return 5Y-93.15%

Teladoc Health, Inc. (TDOC) financials — frequently asked questions

What is Teladoc Health, Inc.'s annual revenue?

Teladoc Health, Inc. (TDOC) reported annual revenue of $2.5B in its most recent fiscal year.

What is Teladoc Health, Inc.'s net profit?

Teladoc Health, Inc. (TDOC) reported a net loss of $200.0M in its most recent fiscal year.

What is TDOC EV/EBITDA?

Teladoc Health, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 7.61.

Revenue and earnings of other Medical - Healthcare Information Services stocks

VEEV revenue $3.2BGEHC revenue $20.6BBTSG revenue $12.9BTEM revenue $1.3BHNGE stockHQY revenue $1.3BDOCS revenue $645.0MHTFL stockPRVA revenue $2.1BCERT revenue $419.0MAll Medical - Healthcare Information Services stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNYSE High ROE StocksAll stock screens
TDOC Overview TDOC Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.